Jump to navigation

Draft pandemic treaty could force Big Pharma to share vaccines with developing countries

Major battles lie ahead as negotiations on a new treaty to set rules for production and distribution of life-saving drugs

Negotiations on protocols for a global and national level pandemic response have started with the World Health Organization's (WHO) Intergovernmental Negotiating Body's (INB) publication of a 'zero-draft' of a new pandemic treaty last week.

The draft states that the WHO is 'deeply concerned by the gross inequities' of supply, production and access to Covid-19 vaccines. Its proposal to reserve at least 20% of any tests, vaccines or treatments for use in poorer countries is likely to prompt major pushback from pharmaceutical giants.

Civil society groups say the treaty should compel governments to commit to sharing medical technology and knowhow. It also states that the intellectual property rules that uphold pharmaceutical company monopolies must be waived automatically when a health emergency is declared.

This points to the need for clear enforcement of the treaty which raises another raft of diplomatic questions. The WHO insists the treaty should be legally binding.

The draft cites the backdrop to its recommendations as the 'catastrophic failure of the international community in showing solidarity and equity in response to the novel Covid-19 pandemic'. The final draft is set to be presented at the World Health Assembly in 2024.

Other proposals in the draft include strengthening and sustaining capacities of health systems, cooperation for sustainable and predictable financing, and raising pandemic and public health literacy for pandemic prevention, preparedness, response and recovery.

It also calls for the establishment of the WHO Global Pandemic Supply Chain and Logistics Network to promote production and transfer of technology and know-how.

This network would boost research and development capacities and establish a Pathogen Access Benefit-Sharing System (PABS) to ensure equitable and timely sharing of pathogens with pandemic potential and genomic sequences.



Related Articles

Who will buy?

Barely 12 months ago there was real urgency in efforts to develop Covid-19 vaccine production facilities in Africa, and even United States President Joe Biden backed some kind...


Third wave threatens the continent

Lack of international consensus on the response to the virus multiplies risks to Africa's economies and healthcare

Top African and UN officials are desperately lobbying a divided international system for a US$100 billion emergency fund to combat what they fear will be a third wave...


Jab race hits new snag

Slow and unpredictable supplies and donations continue to disrupt the roll-out of Covid-19 vaccines in Africa. According to the World Health Organization, most vaccine donations have been 'ad...


Whose cure is it anyway?

Industrialised countries are defending funding research to find a vaccine for Covid-19 out of Official Development Assistance funds against a possible challenge from the Organisation for Economic Co-operation...